Myriad Genetics IncNASDAQ
Historical Stock Data
|52 Week High|
|52 Week Low|
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Dec 4, 2017 | 2:43 pm 1 Article Series
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration's (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.